12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. (Q51745126)
Jump to navigation
Jump to search
scientific article published on 12 February 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | 12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. |
scientific article published on 12 February 2018 |
Statements
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis (English)
Elisabetta Degasperi
Alessio Aghemo
Roberta D'Ambrosio
Marta Borghi
Riccardo Perbellini
Stella De Nicola
Giovanna Lunghi
Pietro Lampertico